Predict your next investment

Venture Capital
newtonbiocapital.com

See what CB Insights has to offer

Investments

13

Portfolio Exits

1

Funds

1

About Newton Biocapital

Newton Biocapital is a Belgian venture capital fund focused on financing biotech and life science projects in the "core of Europe" (B, NL, D, F) and Japan for the prevention and treatment of chronic diseases. The fund's approach as lead investor is to support start-up projects, as well as undervalued late-stage projects, in order to mitigate the risks and to create investor value.

Newton Biocapital Headquarter Location

Tervurenlaan 273

Brussels, 1150,

Belgium

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Newton Biocapital News

Newton Biocapital invests in EditForce to develop a unique DNA/RNA editing platform based on PPR protein technology

Jul 1, 2021

TOKYO, JAPAN, July 1, 2021 / EINPresswire.com / — Newton Biocapital (“Newton”), a life sciences investment fund active in Europe and Japan and focused on the treatment and prevention of chronic diseases, has announced its follow-up investment in EditForce, Inc. (“EditForce”) in Japan. As a lead investor, Newton invested EUR 3.1 million (JPY 400 million) in EditForce as part of a total tranche of EUR 10 million. With this investment, EditForce will continue research and development of its unique, proprietary gene-editing platform. Based on pentatricopeptide repeat (PPR) protein technology, the platform enables precise editing of not only DNA but also RNA. Due to its differentiated mode of action, this novel technology has the potential to impact upon a range of industries, including pharmaceutical, agricultural, and biomanufacturing. EditForce owns several pipelines, both with other partners and independently. The focus is currently set on increasing innovation in treatments for RNA abnormality diseases, with EditForce developing a wide range of applications in other therapeutic fields as well. Takashi Ono, CEO of EditForce: “We’re very pleased to be supported by Newton, which has a wealth of investment experience and achievements in the biotechnology and life science businesses. We have our unique gene editing platform technology, especially advantageous to editing abnormal RNAs. We have already acquired significant drug efficacy data for genetic disease model animals, and will continue to take this opportunity to further acquire data and enhance pipelines.” Yao Li, Investment Director at Newton: “EditForce’s unique PPR-based approach for gene editing enables not only DNA editing but also RNA editing. Their recent proof of concept achievement and follow-up studies on RNA abnormality disease demonstrates the great potential of the technology. We believe it will trigger strong market interest in the medical field and beyond, eventually providing an effective alternative solution to CRISPR-Cas9.” Alain Parthoens, Managing Partner of Newton: “We’re pleased to be supporting this extremely promising technology emerging from Japan’s world-class academic sphere. We see enormous benefit to connecting Japanese life sciences with European financing, as the synergy between the two enables the development of innovative solutions, such as EditForce’s PPR protein technology, with the potential to improve lives around the world.” About EditForce Launched in 2015 at Kyushu University, EditForce is developing a proprietary DNA/RNA editing technology known as PPR protein platform technology. With the vision of “New Tools Lead to a New World”, the company is committed to offering this new DNA/RNA manipulating tool to a wide range of bio-related industries including medical, chemical, and agricultural. For more information, please visit: https://www.editforce.co.jp/en/ About PPR platform technology PPR is a protein that was discovered in plants, which regulates the gene expression by binding RNA or DNA in a sequence-specific manner. PPR proteins are also found in humans and yeasts, where they have similar functions to those of plants. Dr. Takahiro Nakamura (Professor, Kyushu University, and the advisor of EditForce) and Dr. Yusuke Yagi (CTO, EditForce) focused on PPR proteins and elucidated the recognition mode of RNA/DNA by PPR proteins. This elucidation paved the way to a new technology for the rational design of artificial PPR proteins targeted to specific RNA/DNA sequences. Versatile DNA/RNA editing tools can be created by integrating the PPR protein with various enzymes. About Newton Biocapital Brussels, Belgium; Alain Parthoens, Managing Partner Newton Biocapital is a Venture Capital Firm incorporated in Belgium in 2017, focused on financing biotech and life science projects in Europe and Japan for the prevention and treatment of chronic diseases. The fund’s approach as a lead investor is to support promising start-up projects as well as neglected or undervalued late-stage projects, in order to mitigate the risks and to create investor value. Newton’s portfolio includes a mix of European and Japanese companies, and the leadership team consists of specialists with long-standing management and investor experience who coach bio-entrepreneurs through the development stages of their projects. Newton Biocapital’s mission is to generate substantial financial and societal value by providing innovative and affordable solutions to patients. https://www.newtonbiocapital.com/ Ann Van Gysel

Newton Biocapital Investments

13 Investments

Newton Biocapital has made 13 investments. Their latest investment was in PRISM BioLab as part of their Series C - IV on September 9, 2021.

CBI Logo

Newton Biocapital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/9/2021

Series C - IV

PRISM BioLab

$11.85M

Yes

2

6/22/2021

Series A

NeuVasQ Biotechnologies

$23.88M

Yes

3

5/7/2021

Series B

EditForce

$7.33M

No

5

2/24/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

11/12/2020

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/9/2021

6/22/2021

5/7/2021

2/24/2021

11/12/2020

Round

Series C - IV

Series A

Series B

Seed VC

Seed VC

Company

PRISM BioLab

NeuVasQ Biotechnologies

EditForce

Subscribe to see more

Subscribe to see more

Amount

$11.85M

$23.88M

$7.33M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

3

5

10

10

Newton Biocapital Portfolio Exits

1 Portfolio Exit

Newton Biocapital has 1 portfolio exit. Their latest portfolio exit was Perseus Proteomics on June 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/22/2021

IPO

$991

3

Date

6/22/2021

Exit

IPO

Companies

Valuation

$991

Acquirer

Sources

3

Newton Biocapital Fund History

1 Fund History

Newton Biocapital has 1 fund, including Newton Biocapital I Pricaf Privee.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/7/2019

Newton Biocapital I Pricaf Privee

5

Closing Date

1/7/2019

Fund

Newton Biocapital I Pricaf Privee

Fund Type

Status

Amount

Sources

5

Newton Biocapital Team

1 Team Member

Newton Biocapital has 1 team member, including current Founder, Managing Partner, Alain Parthoens.

Name

Work History

Title

Status

Alain Parthoens

Founder, Managing Partner

Current

Name

Alain Parthoens

Work History

Title

Founder, Managing Partner

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.